Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:4905 |
Name | pancreatic carcinoma |
Definition | A pancreas cancer that derives_from epithelial cells located_in the pancreas. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | ABT-348 | pancreatic carcinoma | not applicable | detail... |
SMAD4 loss | SD-093 | pancreatic carcinoma | sensitive | detail... |
Unknown unknown | BMS-906024 | pancreatic carcinoma | not applicable | detail... |
Unknown unknown | Tepotinib | pancreatic carcinoma | not applicable | detail... |
ERBB2 over exp | HER2 CAR-T cells | pancreatic carcinoma | predicted - sensitive | detail... |
Unknown unknown | Gemcitabine + MU380 | pancreatic carcinoma | not applicable | detail... |
Unknown unknown | Lexatumumab + PF-573228 | pancreatic carcinoma | not applicable | detail... |
Unknown unknown | UNC0642 | pancreatic carcinoma | not applicable | detail... |
ERBB2 over exp | ADC ST8176AA1 | pancreatic carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Suspended | USA | 0 |
NCT01537107 | Phase I | Sirolimus + Vismodegib | Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT01663272 | Phase I | Cabozantinib + Gemcitabine | A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT01954732 | Phase I | Metformin | Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery | Withdrawn | 0 | |
NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02268825 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab | Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers | Terminated | USA | 0 |
NCT02807844 | Phase Ib/II | MCS110 + Spartalizumab | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | 10 |
NCT02847000 | Phase 0 | Decitabine + Tetrahydrouridine | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer | Completed | USA | 0 |
NCT02930902 | Phase I | Paricalcitol + Pembrolizumab Gemcitabine + Nab-paclitaxel + Paricalcitol + Pembrolizumab | Preoperative Pilot Study to Assess Safety and Immunological Effect of Pembrolizumab (Keytruda) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT02960594 | Phase I | INO-1400 + INO-9012 INO-1400 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse | Completed | USA | 0 |
NCT03752398 | Phase I | XmAb23104 | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Recruiting | USA | 0 |
NCT03825289 | Phase I | Hydroxychloroquine + Trametinib | Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer (THREAD) | Recruiting | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Recruiting | USA | 0 |
NCT04386057 | Phase II | Hydroxychloroquine + LY3214996 LY3214996 | LY3214996 +/- HCQ in Pancreatic Cancer | Recruiting | USA | 0 |